Singapore’s Nationwide Genetic Carrier Screening Program Offers a Blueprint for Diverse Asian Populations

Every couple hopes for a healthy child, yet for some, the risk of passing on a serious inherited disease remains hidden until it is too late to change the reproductive course. A new study published in BMC Medicine describes how Singapore has begun tackling this problem head-on with a nationwide reproductive carrier screening program designed specifically for Asian populations, whose genetic diversity has long been underrepresented in genomic medicine. The initiative, led by researchers from the SingHealth Duke-NUS Institute of Precision Medicine and KK Women’s and Children’s Hospital, offers one of the most detailed real-world accounts to date of how population-scale genetic screening can be launched in a multiethnic society, from the design of the gene panel to the delicate work of community and religious engagement.

Carrier screening is based on a simple biological premise. Many severe genetic disorders, including thalassemias, metabolic conditions, and neuromuscular diseases, follow an autosomal recessive inheritance pattern, meaning a child is affected only when both parents carry a pathogenic variant in the same gene. Carriers themselves are typically completely healthy, with no symptoms and often no family history, which is precisely why untargeted testing has historically missed so many at-risk couples. When both members of a couple are carriers of variants in the same gene, each pregnancy carries a 25 percent chance of being affected. Knowing this risk in advance opens a range of reproductive options, from preimplantation genetic testing during in vitro fertilization to prenatal diagnosis, informed family planning, and preparation for the medical care an affected child might need.

What distinguishes the Singapore program is its deliberate tailoring to Asian genetic diversity. Rather than adopting a panel built around variants common in European populations, the team designed a customized 112-gene panel targeting recessive diseases that are population-specific to the major ancestral groups represented in the country, including Chinese, Malay, Indian, and other Asian communities. This approach reflects a growing recognition in genomics that variant databases and screening panels calibrated on European data perform poorly elsewhere, both missing genuine carriers and generating confusing results from variants that behave differently across ancestries. Singapore, with its compact geography and well-characterized multiethnic population, provides an ideal setting to demonstrate how precision medicine can be adapted to Asian diversity rather than imported wholesale from Western frameworks.

The program operates nationwide, and its pilot phase began in September 2024. Participants receive culturally tailored online education about the screening program before providing samples, and results are returned with genetic counseling and a full discussion of reproductive options. The numbers reported so far illustrate both the appetite for such testing and the practical realities of implementation. Since the pilot began, 1,619 couples have registered interest in the program, and 60 percent of those deemed eligible went on to participate. Among the 550 couples who had received their results at the time of reporting, six couples, or 1.0 percent, were identified as being at increased risk of having a child affected by a recessive genetic condition. That figure, while small in absolute terms, represents couples who now have the knowledge to make fully informed reproductive decisions, something that would otherwise have remained invisible to them.

Beyond the laboratory and clinic, the research team invested heavily in understanding how the wider community views genetic screening, recognizing that a program’s success depends as much on social acceptance as on scientific accuracy. The researchers surveyed 1,002 community members, including both couples who had participated in the program and members of the general public. The results showed that interest in carrier screening was high, with 59 percent of respondents expressing interest across the cohort. However, the survey also revealed important fault lines: awareness of carrier screening, intent to participate, and understanding of the implications for reproductive options differed significantly by sociodemographic factors such as ancestry and religion. These findings underscore that a one-size-fits-all communication strategy would leave parts of the population behind, potentially exacerbating existing health inequities rather than reducing them.

Religious and cultural sensitivity emerged as a central theme of the implementation effort. The team engaged directly with religious leaders, whose support for the program was indicated through the engagement process, a step that reflects the realities of implementing reproductive genetics in a society where religious beliefs can shape attitudes toward prenatal testing and reproductive choice. By building these relationships before scaling up, the program aimed to ensure that its messaging and services would be culturally appropriate and that communities would not feel targeted or stigmatized by screening offers. This kind of groundwork is often overlooked in genomic medicine programs, which tend to emphasize technical validation over social license, but the Singapore experience suggests the two are inseparable.

The healthcare professional perspective revealed a different set of challenges. Among 113 healthcare professional respondents, there was broad acknowledgment that carrier screening will become routine in medical care, a consensus that mirrors international trends as sequencing costs fall and professional guidelines expand. Yet the same respondents reported limited confidence and limited resources for delivering this service. This gap between expected demand and workforce readiness is a familiar problem in genomics. Genetic counseling capacity is scarce in most countries, and frontline physicians in obstetrics, general practice, and family medicine often receive little training in interpreting carrier screening results or communicating residual risk. The Singapore findings suggest that any country contemplating population screening must budget as much for professional education and counseling infrastructure as for the genetic tests themselves.

The program sits within a broader national strategy. It forms part of Singapore’s National Precision Medicine initiative, a multi-phase government effort to build genomic infrastructure tailored to Asian populations, supported by the National Research Foundation and the Ministry of Health. Funding for the carrier screening program itself came through the Temasek Foundation and strategic academic funds, with the community questionnaire study supported by Singapore’s Social Science Research Council. This layered funding model, combining philanthropy, national research investment, and health system integration, may prove instructive for other countries weighing how to finance genomic screening programs that are expected to run for decades rather than years.

The technical architecture of the program also merits attention. The 112-gene panel was developed with contributions from the hospital’s DNA Diagnostic and Research Laboratory and the national diagnostics manufacturing hub, with a dedicated reporting system built at the National Heart Centre Singapore. Variant classification follows established frameworks from the American College of Medical Genetics and Genomics, and population frequency data drawn from resources such as the Genome Aggregation Database inform the interpretation of variants in the local context. Ethics approval was obtained from the SingHealth Centralised Institutional Review Board, and the program’s design incorporated input from clinical geneticists, genetic counselors, and genetics nurses who reviewed the educational content delivered to participants. The result is an end-to-end system in which education, testing, reporting, and counseling are integrated rather than bolted together.

The authors conclude that these early outcomes and community engagement findings are now guiding the expansion of population-based carrier screening in Singapore, but they are explicit that this expansion is contingent on addressing practical challenges through equitable outreach and professional training. The study’s significance extends well beyond the island nation. Most of the world’s population lives in Asia, yet genomic screening programs have been designed and validated overwhelmingly in Europe, North America, and Australia. Singapore’s experience demonstrates that population-specific panels, culturally grounded engagement, and honest assessment of healthcare workforce limitations can be combined into a workable national program. As other Asian countries develop their own precision medicine strategies, the Singapore model offers both a technical template and a cautionary lesson: the genetics may be the easy part, and the harder work lies in earning the trust of diverse communities and preparing clinicians to translate genomic knowledge into genuinely useful reproductive choices.

Subject of Research: Implementation of population-based reproductive carrier screening for diverse Asian populations in Singapore

Article Title: Implementing reproductive carrier screening to include diverse Asian populations: insights from Singapore

Article References: Bylstra, Y., Juann, M. Y., Teo, J. X., Goh, J., Choi, C., Chan, S., Song, C., Yin Goh, J. C., Siew Chai, N. B., Lieviant, J. A., Toh, H. J., Chan, S. H., Blythe, R., Menezes, M., Yang, C., Hodgson, J., Graves, N., Sng, J., Lim, W. W., … Jamuar, S. S. (2026). Implementing reproductive carrier screening to include diverse Asian populations: insights from Singapore. BMC Medicine. https://doi.org/10.1186/s12916-026-05286-w

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05286-w

Keywords: reproductive carrier screening, genetic testing, precision medicine, Singapore, Asian populations, autosomal recessive disease, genetic counseling, population screening, community engagement, healthcare professionals, gene panel, thalassemia